Subei Hospital"80" than fruit and doctoral students in top international academicjournal "The Lancet" Subsidiary professional journals, "LancetOncology" published research papers, received wide attention from theinternational academic community and clinicians. This paper solves theUnited States Food and Drug Administration and the European Drug Administrationtwo authorities on tumor drugs that exist in dispute. It is understood that the past 20 years,the Chinese people in the magazine published 18 scholarly articles only. InYangzhou medical profession, the paper also created a precedent for the city'shigh level of SCI papers.
Thismagazine rejection rate over 90%, but it passed the doctoral thesis.
October1, the top international medical journals, "Lancet Oncology",published research papers titled "tyrosine kinase inhibitor and antaciddrug combination therapy of interaction", quickly caught internationalacademics and clinicians attention, and the first author of the paper is thefruit of more than Yangzhou Medical PhD.
"Lancet"magazine is one of the world's most prestigious medical journals, its impact inthe medical community even more than the "natural" and "science",allegedly rejection rate over 90%, "a year Thereare 12, each published paper only 20-30 papers. "If I said," Usuallymany research papers into the hands of reviewers simply can not, in the firstinstance it was banning federal funding. "In late August, the paperreceived the magazine show ,October 1, the paper was officially published and published.《Recommended reading："LancetOncology": China, India is facing a cancer crisis 》
Thispaper is the study of cancer drugs, if used in clinical, or prolong life.
If I introducedher research paper with the Shanghai University of Traditional Chinese MedicineClinical Research Center for Drug co-authored, the main research is therationalization of cancer patients medication problems. Papernotes that cancer patients, 20% -33% of the population will suffer fromgastroesophageal reflux disease while patients suffering from this disease needto take antacids, which is in the treatment of cancer combined acid treatment. However,many new oral cancer therapy - tyrosine kinase inhibitor, is limited by theacidic environment of the gastrointestinal tract, "while taking the twodrugs will reduce the oral absorption of anticancer drugs, thereby affectingthe clinical efficacy of the drug." I Ifyou change a more popular explanation: that is, inappropriate use may result inoverall survival in patients with tumor reduction.
Accordingto the paper, more than fruit, if you avoid antacids restrictions on new oralcancer treatment drug, drug combination therapy can improve efficacy, "thepaper if applied in clinical medicine, there will be a lot of cancer patientsreceive bettertreatment, their survival will be extended. "
In addition,the paper also addresses the drug in the tumor context, between the UnitedStates FDA (Food and Drug Administration) and the European EMA (EMA) controversy."Lancet"senior editor Dr. Coburn also affirmed the importance and influence of thestudy.
SCIanother one quality article Dr. Yu Guo also published in the Official Journalof the American Pharmaceutical will The AAPS Journal this year.
NewsWikipedia: "The Lancet" (The Lancet) is one of the world's mostprestigious medical journals in the entire medical profession, speak"Lancet" has maintained the independence and authority. "LancetOncology" is the "Lancet" child's highest impact factor journalsand the top 194 in the world oncology journal, it is one of the top journals inthe field of oncology most influential.
"TheLancet" has spawned several ancillary professional journals, these journaltitles are beginning Lancet, such as "Lancet Neurology", "LancetOncology", "Lancet Infection disease "," Lancetrespiratory medicine "," Lancet Diabetes and Endocrinology"and" The Lancet Global Health. "
Rainbow Protective Products Company is a professional Chinese manufacturer of personal protective product and medical disposables. our products are increasingly being used in medical, food, pharmaceutical, electronics and other industries. We now have a large number of clients from nearly 30 different countries and regions around the world, including the US, Japan, Australia, Europe, South America and Southeast Asia.
Mobile:13871337419 Tel:86-27-87739381 Fax:86-27-87739382